Journal article

Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W Roberts, John F Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D Hilger, Jane Huang, Constantine S Tam

Blood | AMER SOC HEMATOLOGY | Published : 2020

Abstract

Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who were either treatment-naïve (TN) or had relapsed/refractory (R/R) disease. Patients had disease requiring treatment per International Workshop on Waldenström Macroglobulinemia (IWWM) criteria. Treatment was 160 mg of oral zanubrutinib twice daily (n = 50) or 320 mg once daily (n = 23). Efficacy endpoints included overall response rate (ORR) and very good partial response/complete response (VGPR/CR) rates per IWWM-6 criteria (with modification of VGP..

View full abstract

Grants

Funding Acknowledgements

The authors thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centers. This study was supported by research funding from BeiGene (Beijing) Co., Ltd. (Beijing, China). Medical writing and editorial assistance were funded by BeiGene and provided by Gordon Bray and Bio Connections (Chicago, IL).